

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Figure 1.



\*(R)-configuration

\*\*\*(R)- or (S)-configuration

wherein

$R^1$ ,  $R^2$  and  $R^3$  are each independently of the others an aliphatic hydrocarbon radical having from 7 to 21 carbon atoms,

$n$  is 0 or 1,

As is the amidically bonded residue of a (D)- or (L)-amino acid or of a (D)- or (L)-amino acid derivative from the group consisting of Gly, Ala, Ser, Thr, Asp, Asp( $R^5$ ), Glu, Glu( $R^5$ ), Glu, Glu( $R^5$ ) and Glu( $R^5$ )<sub>2</sub>, and

$R^4$  and  $R^5$  are each independently of the other the amidically bonded radical of an unsubstituted or carboxy-substituted  $\alpha$ -amino-C<sub>2</sub>-C<sub>3</sub>alkanesulfonic acid.





Figure 2



JBT3002,  $C_{55}H_{102}N_4O_{14}S_3Na_2$  (1185.6)





Figure 3





Figure 4




MLV-JT3002

(A)

- 10' 20' 30' 4h 24h


133 -  
71 -  
42 -  
31 -



45 kD  
41 kD  
39 kD

kDa

$\beta$ -actin



IFN  $\gamma$   
LPS  
MLV-JT3002

+ + - + + + + +  
- 15' - - - - -  
- - - 5' 10' 20' 30' 120'

(B)

133 -  
71 -  
42 -  
31 -



45 kD  
41 kD  
39 kD

kDa

$\beta$ -actin




Figure 5








Figure 6




Figure 7






Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15







Figure 16





Figure 17




Figure 18






Figure 19



COPY

CONFIDENTIAL

PBS followed by CPT-11

Oral ACP-PE followed by CPT




Figure 20

O I P E  
MAR 15 2004  
PATENT & TRADEMARK OFFICE

COPY CONFIDENTIAL





Figure 21



# ILEUM





## IL-15 RT-PCR




Fig 23